KRAS and cancer: These experiments showed that heterozygous expression of Rnpc3 is sufficient to markedly restrict the growth and proliferation of cancers driven by a variety of pro-proliferative, pro-survival pathways (KRAS/MAPK and STAT3), without any impact on healthy tissues.